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ABSTRACT
Our laboratory previously developed a highly-invasive, triple-negative breast 
cancer (TNBC) variant using serial orthotopic implantation of the human MDA-MB-231 
cell line in nude mice. The isolated variant was highly-invasive in the mammary gland 
and lymphatic channels and metastasized to lymph nodes in 10 of 12 mice compared to 
2 of 12 of the parental cell line. In the present study, the tumor-selective telomerase 
dependent OBP-401 adenovirus was injected intratumorally (i.t.) (1 × 108 PFU) when 
the high-metastatic MDA-MB-231 primary tumor expressing red fluorescent protein 
(MDA-MB-231-RFP) reached approximately 500 mm3 (diameter; 10 mm). The mock-
infected orthotopic primary tumor grew rapidly. After i.t. OBP-401 injection, the 
growth of the orthotopic tumors was arrested. Six weeks after implantation, the 
fluorescent area and fluorescence intensity showed no increase from the beginning 
of treatment. OBP-401 was then injected into high-metastatic MDA-MB-231-RFP 
primary orthotopic tumor growing in mice which already had developed metastasis 
within lymphatic ducts. All 7 of 7 control mice subsequently developed lymph node 
metastasis. In contrast, none of 7 mice which received OBP-401 had lymph node 
metastasis. Seven of 7 control mice also had gross lung metastasis. In contrast, 
none of the 7 mice which received OBP-401 had gross lung metastasis. Confocal laser 
microscopy imaging demonstrated that all control mice had diffuse lung metastases. 
In contrast, all 7 mice which received OBP-401 only had a few metastatic cells in the 
lung. OBP-401 treatment significantly extended survival of the treated mice.
INTRODUCTION
Triple-negative breast cancer (TNBC) lack estrogen, 
progesterone, and ErbB2 receptors, and is almost always 
resistant to therapy [1, 2]
We previously described the development of a 
highly-invasive, triple-negative breast cancer (TNBC) 
variant using serial orthotopic implantation of MDA-
MB-231 human breast cancer in nude mice. The isolated 
variant was highly invasive in the mammary gland and 
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metastasized to lymph nodes in 10 of 12 mice compared 
to 2 of 12 of the parental cell line [3].
Surgical resection of the MDA-MB-231 high-
metastatic variant primary tumor in orthotopic models 
resulted in rapid and enhanced lymphatic trafficking of 
residual cancer cells and subsequent extensive lymph-
node and lung metastasis that did not occur in the non-
surgical mice [4].
The parental MDA-MB-231 grew as spindle-shaped 
cells on plastic dishes. In contrast, highly-metastatic MDA-
MB-231 cells, derived from lymph node metastasis, grew 
mostly in suspension suggesting that high-metastatic 
MDA-MB-231 became undifferentiated, therefore more 
aggressive and metastatic. After wounding confluent 
co-cultures on plastic, the high-metastatic variant 
expressing red fluorescent protein MDA-MB-231-RFP 
cells significantly migrated and invaded more extensively 
compared with low-metastatic parental MDA-MB-231 
expressing green fluorescent protein (MDA-MB-231-GFP) 
cells, as imaged by color-coded confocal microscopy [5].
We have previously developed a genetically-
engineered GFP-expressing telomerase-specific 
adenovirus, OBP-401, which can selectively illuminate 
and kill cancer cells [6–14].
We previously demonstrated that targeting human 
cancer in nude mice with OBP-401 enabled effective 
fluorescence-guided surgery (FGS) of many tumor types 
in orthotopic models [6–14]. OBP-401 enabled complete 
resection and prevented local recurrence and greatly 
inhibited lymph node metastasis of the high-metastatic 
MDA-MB-231 variant TNBC [15].
In the present report we demonstrate that OBP-401 
alone can inhibit primary-tumor growth and metastasis of 
the high-metastatic MDA-MD-231 variant.
RESULTS AND DISCUSSION
Efficacy of OBP-401 against high-metastatic 
MDA-MB-RFP orthotopic primary tumors
OBP-401 was injected intratumorally (1 × 108 
PFU) when high-metastatic MDA-MB-231-RFP primary 
tumors reached approximately 500 mm3 (diameter; 10 
mm) (Figure 1). The mock-infected orthotopic primary 
tumor grew rapidly. After intra-tumoral (i.t.) OBP-401 
injection, the growth of the orthotopic primary tumors was 
arrested. Six weeks after implantation, the fluorescent area 
and fluorescence intensity of the OBP-401-treated tumors 
showed no increase from the beginning of treatment.
Efficacy of OBP-401 against high-metastatic 
MBA-MB-231 lymphatic trafficking and 
metastasis
OBP-401 was injected into high-metastatic MDA-
MB-231-RFP primary tumors growing in mice which had 
already developed metastasis in lymphatic ducts (Figure 
2A). OBP-401 labeled metastatic cancer cells with GFP 
in lymphatic ducts, as well as the primary tumors by 3 
days after injection (Figure 2B). Intravital real-time 
GFP imaging demonstrated that metastatic cancer cells 
were killed after 3 cycles of OBP-401 treatment (Figure 
2B). All 7 of 7 control mice had lymph node metastasis, 
6 weeks after orthotopic implantation (Figure 2C). In 
contrast, none of 7 mice which were treated with OBP-
401 had lymph-node metastasis (Figure 2C).
OBP-401 inhibits lung metastasis of high-
metastatic MDA-MB-231 RFP
Seven of 7 control mice had gross lung metastasis 
six weeks after orthothopic implantation (Figure 3A and 
3B). In contrast, none of the 7 mice which were treated 
with OBP-401 had gross lung metastasis (Figure 3C and 
3D). Confocal laser microscopy imaging demonstrated 
that all control mice had diffuse lung metastases (Figure 
3E, 3G). In contrast, the 7 mice which were treated with 
OBP-401 had only a few metastatic cells in the lung 
(Figure 3F, 3H). The fluorescent area and fluorescence 
intensity in the lungs was greatly reduced by OBP-401 
(Figure 3I).
OBP-401 treatment significantly extended survival 
of the treated mice (Figure 3J). Thus, injection of OBP-
401 into the primary tumor inhibited local and distant 
metastasis and prolonged the survival rate.
TNBC is a recalcitrant disease with few effective 
treatment options in the clinic [1, 2]. Although standard 
chemotherapy drugs have had some effect with claims of 
“profound prevention of experimental brain metastasis” 
of breast cancer [16], such treatment is of limited efficacy.
OBP-401 appears to be highly effective against 
primary growth, lymph-node metastasis and lung 
metastasis of a high-metastatic variant of TNBC. The 
parent of OBP-401, OBP-301, has already undergone 
clinical trials demonstrating safety [17]. Clinical 
development of tumor-targeting OBP-401 is warranted.
OBP-401 will be tested on breast cancer patient-
derived orthotopic xenografts (PDOX) [18, 19] in the next 
set of studies.
Previously-developed concepts and strategies of 
highly selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [20–25].
MATERIALS AND METHODS
OBP-401
Telomerase-dependent adenovirus OBP-401 
contains a promoter element of the human telomerase 
reverse transcriptase (hTERT) gene which drives the 
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Figure 1: Efficacy of OBP-401 against primary orthotopic high-metastatic MDA-MB-231-RFP. OBP-401 was injected 
intratumorally (1 × 108 PFU) when primary tumors reached approximately 500 mm3 (diameter; 10 mm). A. Representative whole-body 
images of mock-infected orthotopic primary tumor. B. Representative whole-body images of orthotopic tumors before and after injection 
of OBP-401. 
expression of E1A and E1B genes linked to an internal 
ribosome entry site for selective replication only in cancer 
cells. The GFP gene of the virus is driven by the CMV 
promoter, was constructed as previously described [6–14].
Cell culture
Parental and high-metastatic variants of MDA-
MB-231P-RFP were maintained and cultured in DMEM 
medium with 10% fetal bovine serum (FBS) and 5% 
penicillin/streptomycin [5].
Mice
Athymic nude mice (AntiCancer, Inc., San Diego, 
CA) were kept in a barrier facility under HEPA filtration. 
Mice were fed with autoclaved laboratory rodent diet 
(Tecklad LM-485, Western Research Products). All animal 
(Continued )
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studies were conducted in accordance with the principals 
and procedures outlined in the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals 
under assurance A3873– 01.
Establishment of orthotopic, highly metastatic 
breast cancer
Initially, MDA-MB-231-RFP cells (1 × 107 cells/
site) were injected subcutaneously in the flank of nude 
mice. For orthotopic transplantation, fragments of the 
harvested subcutaneous tumor were grafted in a mammary 
gland of nude mice. After growth, the tumor was resected. 
Residual cancer cells grew into a tumor which was 
harvested and divided into fragments and re-implanted 
into a mammary gland of nude mice. After the tumor 
metastasized to lymph nodes, it was harvested and divided 
into fragments and re-implanted into mammary gland 
of nude mice. After growth, the orthotopic tumor was 
resected. The residual cancer cells formed primary and 
metastatic tumors. The metastasis was harvested, divided 
into fragments and re-implanted into the mammary gland 
Figure 1 (Continued ): C. Representative whole-body images of mock-infected and OBP-401-treated orthotopic tumors 6 weeks 
after tumor implantation. D. Comparison of primary tumor growth of mock-infected and OBP-401-treated mice. Fluorescent area and 
fluorescence intensity are calculated with ImageJ software. Data are shown as average ± SD. N = 7.
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of nude mice. Highly-metastatic MDA-MB-231 tumors 
were developed after seven orthotopic transplantations 
described above [3].
OBP-401 treatment
OBP-401 (1 × 108 PFU) was intratumorally injected 
into the orthotopic tumor every 3 days.
In vivo whole-body/whole-tumor Imaging
For whole-body or whole-tumor imaging, an 
Olympus small animal imaging system, OV-100, was 
used. The OV100 small animal imaging system (Olympus 
Corp., Tokyo, Japan), was used. The OV100 contains 
an MT-20 light source (Olympus Biosystems, Planegg, 
Germany) and DP70 CCD camera (Olympus), for whole 
Figure 2: Efficacy of OBP-401 against lymph-node metastasis of high-metastatic MDA-MB-231-RFP. OBP-401 was 
injected intratumorally (1 × 108 PFU) when the mice already developed metastasis in lymphatic ducts. A. Representative whole-body time-
course images of mock-infected orthotopic tumors. B. Representative whole-body time-course images of orthotopic tumors after injection 
of OBP-401. 
(Continued )
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body, as well as subcellular imaging in live mice [26–29]. 
The optics of the OV100 have been specially developed 
for macroimaging as well as microimaging with high 
light-gathering capacity. Four individually optimized 
objective lenses, parcentered and parfocal, provide a 105-
fold magnification range. High-resolution images were 
captured directly on a PC (Fujitsu Siemens, Munich, 
Germany). Images were processed for contrast and 
brightness and analyzed with the use of Paint Shop Pro 8 
and CellR [30].
Statistical analysis
Data are shown as means ± standard deviation 
(SD). For comparison between two groups, significant 
differences were determined using the Student’s t-test. 
Figure 2: (Continued ) C. Representative whole-body images of mock-infected and OBP-401-treated mice 6 weeks after tumor 
implantation. D. Comparison of lymphatic metastasis of mock-infected and OBP-401-treated mice. Fluorescent area and fluorescence 
intensity of lymph-node metastasis are calculated with ImageJ software. Data are shown as average ± SD. N = 7.
Oncotarget85279www.impactjournals.com/oncotarget
Figure 3: Efficacy of OBP-401 on lung metastasis of high-metastatic MDB-MB-231-RFP and survival. A-D. Representative 
whole-lung images of mock-infected (A, B) and OBP-401-treated mice (C, D). A, C: Bright-field; B, D: fluorescence images. Images 
were acquired with the OV100 whole-body imaging system (Olympus, Japan). E and F. Representative single-cell images of lung in 
mock-infected (E) and OBP-401-treated mice (F). E1, F1: Lung tissue imaged by autofluorescence; E2: F2; fluorescence images. E3, F3; 
Composite images from E1, F1 and E2, F2. G and H. Representative H&E. images of lung in mock-infected (G) and OBP-401-treated 
mice (H). 
(Continued )
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P values of < 0.05 were considered significant. Pearson 
chi-square analysis was used to compare the rate of lymph 
node metastasis between control and OBP-401-treated 
groups. Statistical analysis for over-all survival was 
performed using the Kaplan-Meier test along with log-
rank test.
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